Drug intelligence / Profile preview

DengiAll

Development stage: Unknown
Lead developer: Panacea Biotec
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

DengiAll is a tetravalent recombinant live attenuated vaccine designed to protect against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). It is being developed as India's first indigenous dengue vaccine and aims to address the significant public health burden of dengue fever in tropical and subtropical regions. The vaccine is based on the TV003/TV005 strain originally developed by the National Institutes of Health (NIH) and has been further advanced by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR). Its mechanism involves immunostimulation to induce protective immunity against all four serotypes. As of April 2025, it is undergoing Phase 3 clinical trials across multiple sites in India[1][3][4][5][7].

Brand names: DengiAll
Other names: Tetravalent dengue Vaccine Panacea Biotec

Beyond the preview

Go deeper on DengiAll.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DengiAll.

Explore the full profile